SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

With no major difference for the quarter endedJune 2022 , the total revenue stood at Rs. 7294.60  millions.Profit saw a slight increase of 8.47%to Rs. 1156.30  millions from Rs. 1066.00 millions.Operating profit for the quarter ended June 2022 rose to 1757.20 millions as compared to 1634.70 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 7294.60 7018.40 3.94 7294.60 7018.40 3.94 32175.10 29204.70 10.17
Other Income 277.90 317.30 -12.42 277.90 317.30 -12.42 762.20 1101.90 -30.83
PBIDT 1757.20 1634.70 7.49 1757.20 1634.70 7.49 8320.50 7079.60 17.53
Interest 6.80 7.90 -13.92 6.80 7.90 -13.92 19.90 35.30 -43.63
PBDT 1750.40 1626.80 7.60 1750.40 1626.80 7.60 8416.40 5318.30 58.25
Depreciation 158.20 175.40 -9.81 158.20 175.40 -9.81 681.90 786.00 -13.24
PBT 1592.20 1451.40 9.70 1592.20 1451.40 9.70 7734.50 4532.30 70.65
TAX 435.90 385.40 13.10 435.90 385.40 13.10 3968.70 1665.40 138.30
Deferred Tax -34.70 -34.80 -0.29 -34.70 -34.80 -0.29 -105.00 78.70 -233.42
PAT 1156.30 1066.00 8.47 1156.30 1066.00 8.47 3765.80 2866.90 31.35
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 24.09 23.29 3.42 24.09 23.29 3.42 25.86 24.24 6.68

Glaxosmithkline Phar Share Price

2491.40 28.65 (1.16%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×